CIK 0001933414 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Mineralys Therapeutics, Inc.
Sign in to watch- Ticker
- MLYS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 841966887
- Phone
- (888) 378-6240
- Business address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,403,032
- in 5 filings, $2.4M under 10b5-1 plans
Net −$5,403,032. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-13 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +4,167 | $14.25 | $59K | 90,198 |
| 2026-04-13 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −14,058 | $26.54 | $373K | 76,140 |
| 2026-04-13 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −6,349 | 19,046 | ||
| 2026-04-13 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −3,542 | 120,417 | ||
| 2026-04-13 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −4,167 | 91,667 | ||
| 2026-04-13 | Congleton Jon Chief Executive Officer | Sale 10b5-1 | −15,730 | $26.83 | $422K | 689,321 |
| 2026-04-09 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +2,170 | $16.00 | $35K | 78,310 |
| 2026-04-09 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −2,170 | $27.38 | $59K | 76,140 |
| 2026-04-09 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −2,170 | 21,706 | ||
| 2026-03-31 | Karydas Daphne Director | Option exercise 10b5-1 | +3,000 | $12.02 | $36K | 9,200 |
| 2026-03-31 | Karydas Daphne Director | Sale 10b5-1 | −3,000 | $25.00 | $75K | 6,200 |
| 2026-03-31 | Karydas Daphne Director | Option exercise · Stock Option 10b5-1 | −3,000 | 41,000 | ||
| 2026-03-31 | Congleton Jon Chief Executive Officer | Sale 10b5-1 | −19,364 | $25.50 | $494K | 760,687 |
| 2026-03-31 | Congleton Jon Chief Executive Officer | Sale 10b5-1 | −55,183 | $26.54 | $1.5M | 705,504 |
| 2026-03-31 | Congleton Jon Chief Executive Officer | Sale 10b5-1 | −453 | $27.05 | $12K | 705,051 |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +58,300 | $24.16 | $1.4M | 5,825,521 |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +310,700 | $23.67 | $7.4M | 5,767,221 |
| 2026-03-17 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +417 | $15.44 | $6K | 76,557 |
| 2026-03-17 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −417 | $25.65 | $11K | 76,140 |
| 2026-03-17 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −417 | 5,000 |
Page 5 of 17 · 321 trades